OMERS ADMINISTRATION Corp Purchases Shares of 15,911 Insulet Corporation $PODD

OMERS ADMINISTRATION Corp purchased a new position in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 15,911 shares of the medical instruments supplier’s stock, valued at approximately $2,422,000.

A number of other large investors have also modified their holdings of PODD. BlackRock Inc. purchased a new position in shares of Insulet in the 2nd quarter valued at approximately $1,018,582,000. State Street Corp grew its position in Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after purchasing an additional 65,317 shares during the last quarter. Geode Capital Management LLC grew its position in Insulet by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after purchasing an additional 41,019 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after buying an additional 141,167 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after buying an additional 1,011,369 shares during the period.

Insulet Trading Down 1.6%

NASDAQ PODD opened at $143.05 on Wednesday. The company has a market capitalization of $9.92 billion, a PE ratio of 26.74, a P/E/G ratio of 1.15 and a beta of 1.10. The company has a fifty day moving average of $154.52 and a 200 day moving average of $182.80. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period last year, the firm earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PODD. Wall Street Zen lowered shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 9th. Robert W. Baird set a $175.00 price target on Insulet in a research report on Thursday, August 6th. Truist Financial reiterated a “hold” rating and set a $153.00 price target (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Bank of America cut their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Raymond James Financial restated an “outperform” rating and issued a $180.00 price objective on shares of Insulet in a research note on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $195.40.

Insiders Place Their Bets

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.36% of the company’s stock.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet CEO Ashley McEvoy purchased 1,100 shares at an average price of $147.47, an investment of approximately $162,200. The purchase increased her direct holdings by about 5% and may signal management confidence following the stock’s substantial decline. Insulet CEO share purchase
• Positive Sentiment: Recent operating results remain a support: Insulet’s latest quarterly report exceeded analyst expectations for both earnings and revenue, with revenue rising 23.5% year over year and margins improving. The company’s growth outlook, however, has been reset, making execution key to the investment case.
• Neutral Sentiment: Reported short-interest data shows zero shares short and a zero-day short-interest ratio, but the stated month-over-month change is “NaN,” indicating the data is likely incomplete or erroneous. It should not be interpreted as evidence of a meaningful short-covering or short-selling trend.
• Negative Sentiment: Pomerantz announced that a securities class action has been filed in federal court against Insulet and certain officers. The proposed class covers investors who purchased securities from February 21, 2025, through May 26, 2026, and alleges violations of federal securities laws. The allegations have not been proven. Pomerantz class action announcement
• Negative Sentiment: Several firms issued substantially similar notices encouraging investors to seek lead-plaintiff status by August 31. The claims center on alleged manufacturing deficiencies and two voluntary corrections or recalls affecting millions of Omnipod devices, as well as assertions that Insulet overstated manufacturing quality and growth prospects. The volume of legal announcements increases reputational, litigation-cost, and potential-liability concerns, even though the notices themselves do not establish wrongdoing.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.